These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37012549)

  • 1. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.
    Shenderov E; De Marzo AM; Lotan TL; Wang H; Chan S; Lim SJ; Ji H; Allaf ME; Chapman C; Moore PA; Chen F; Sorg K; White AM; Church SE; Hudson B; Fields PA; Hu S; Denmeade SR; Pienta KJ; Pavlovich CP; Ross AE; Drake CG; Pardoll DM; Antonarakis ES
    Nat Med; 2023 Apr; 29(4):888-897. PubMed ID: 37012549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
    Aggarwal C; Prawira A; Antonia S; Rahma O; Tolcher A; Cohen RB; Lou Y; Hauke R; Vogelzang N; P Zandberg D; Kalebasty AR; Atkinson V; Adjei AA; Seetharam M; Birnbaum A; Weickhardt A; Ganju V; Joshua AM; Cavallo R; Peng L; Zhang X; Kaul S; Baughman J; Bonvini E; Moore PA; Goldberg SM; Arnaldez FI; Ferris RL; Lakhani NJ
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35414591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.
    Benzon B; Zhao SG; Haffner MC; Takhar M; Erho N; Yousefi K; Hurley P; Bishop JL; Tosoian J; Ghabili K; Alshalalfa M; Glavaris S; Simons BW; Tran P; Davicioni E; Karnes RJ; Boudadi K; Antonarakis ES; Schaeffer EM; Drake CG; Feng F; Ross AE
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):28-35. PubMed ID: 27801901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
    Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
    Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.
    Amori G; Sugawara E; Shigematsu Y; Akiya M; Kunieda J; Yuasa T; Yamamoto S; Yonese J; Takeuchi K; Inamura K
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):767-774. PubMed ID: 33558663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
    Ross RW; Galsky MD; Febbo P; Barry M; Richie JP; Xie W; Fennessy FM; Bhatt RS; Hayes J; Choueiri TK; Tempany CM; Kantoff PW; Taplin ME; Oh WK
    Cancer; 2012 Oct; 118(19):4777-84. PubMed ID: 22282219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer.
    Ryan ST; Zhang J; Burner DN; Liss M; Pittman E; Muldong M; Shabaik A; Woo J; Basler N; Cunha J; Shalapour S; Estrada MV; Karin M; Messer K; Howell S; Kane CJ; Jamieson CAM
    J Transl Med; 2020 May; 18(1):214. PubMed ID: 32466781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High B7-H3 expression is linked to increased risk of prostate cancer progression.
    Bonk S; Tasdelen P; Kluth M; Hube-Magg C; Makrypidi-Fraune G; Möller K; Höflmayer D; Dwertmann Rico S; Büscheck F; Minner S; Heinzer H; Graefen M; Hinsch A; Luebke AM; Dum D; Uhlig R; Schlomm T; Sauter G; Simon R; Weidemann SA
    Pathol Int; 2020 Oct; 70(10):733-742. PubMed ID: 32776718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
    Clark PE; Peereboom DM; Dreicer R; Levin HS; Clark SB; Klein EA
    Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).
    Scheinberg T; Kench J; Stockler M; Mahon KL; Sebastian L; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Centenera MM; Butler LM; Horvath LG
    BMJ Open; 2020 Jan; 10(1):e033667. PubMed ID: 31988233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
    Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H3: a robust target for immunotherapy in prostate cancer.
    Pulido R; López JI; Nunes-Xavier CE
    Trends Cancer; 2024 Jul; 10(7):584-587. PubMed ID: 38839545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer.
    Koshkin VS; Mir MC; Barata P; Gul A; Gupta R; Stephenson AJ; Kaouk J; Berglund R; Magi-Galluzzi C; Klein EA; Dreicer R; Garcia JA
    Invest New Drugs; 2019 Jun; 37(3):559-566. PubMed ID: 31037562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study.
    Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Yoneyama T; Hashimoto Y; Kamimura N
    Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):397-401. PubMed ID: 22890389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.
    Marschner N; Rüttinger D; Zugmaier G; Nemere G; Lehmann J; Obrist P; Baeuerle PA; Wolf A; Schmidt M; Abrahamsson PA; Reinhardt C; Heidenreich A
    Urol Int; 2010; 85(4):386-95. PubMed ID: 20606402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
    Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
    Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
    Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.